Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis

Cabozantinib inhibits tyrosine kinase activity at the MET, AXL, and VEGF receptors and is approved for front-line therapy in metastatic clear cell renal cell carcinoma. Little off-protocol data exist on tolerability and response. The objective of this retrospective study was to assess off-protocol t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemke, Emily A., Shah, Amishi Y., Campbell, Matthew, Tannir, Nizar M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520741/
https://www.ncbi.nlm.nih.gov/pubmed/33343982
http://dx.doi.org/10.6004/jadpro.2019.10.4.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520741/
https://www.ncbi.nlm.nih.gov/pubmed/33343982
http://dx.doi.org/10.6004/jadpro.2019.10.4.2

Ejemplares similares